ONCAlert | Upfront Therapy for mRCC
Videos  >  

Phase III INVICTUS Trial Evaluates Ripretinib in Advanced GIST

Margaret von Mehren, MD
Published Online:5:00 PM, Thu December 26, 2019


Margaret von Mehren, MD, from the Fox Chase Cancer Center, discusses the rationale for evaluating ripretinib (DCC-2618) in patients with heavily pretreated advanced gastrointestinal stromal tumors (GIST) in the phase III INVICTUS trial, which was presented at the European Society for Medical Oncology (ESMO) Congress 2019.

The tumors in patients with GIST are driven by mutations primarily in 2 genes, which include KIT and PDGFRα. There are 3 drugs currently approved by the FDA for the treatment of these patients, including imatinib (Gleevec), sunitinib (Sutent), and regorafenib (Stivarga), von Mehren says. Following treatment with these therapies, many patients are clinically well and healthy enough to proceed with more therapy. However, there is a lack of therapies available following the 3 FDA-approved drugs.

Based on phase I data which showed ripretinib had activity in this patient population, investigators sought to evaluate the agent to see if it could provide meaningful benefit to patients who have at least received the 3 standard drugs previously.
Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.